SCHEMBL2954865

SCHEMBL2954865

CCOc1cc(C=O)cc(OCc2ccccc2)c1-c1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
LMNA P02545 3/20 0.48
TACR2 P21452 1/20 0.48
HTR1A P08908 2/20 0.47
ADRA1D P25100 2/20 0.47
ADRA1A P35348 2/20 0.47
ADRA1B P35368 2/20 0.47
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
SSTR5 P35346 3/20 0.45
ALDH1A1 P00352 4/20 0.45
MAPT P10636 4/20 0.45
NTSR1 P30989 3/20 0.45
PKM P14618 2/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
KCNH2 Q12809 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.44
MAPK1 P28482 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1121685 0.88 ALDH1A1 (0.50) KDM4ETACR2SSTR5ALDH1A1KCNH2
SCHEMBL17535738 0.83 ALDH1A1 (0.46) KDM4ESSTR5ALDH1A1MAPTKCNH2
SCHEMBL2955273 0.83 ALDH1A1 (0.53) KDM4ELMNATACR2ALDH1A1MAPT
SCHEMBL16056243 0.82 ALDH1A1 (0.44) KDM4ETACR2SSTR5ALDH1A1MAPT
SCHEMBL16056410 0.81 KDM4E (0.46) KDM4ELMNATACR2MAOAMAOB
SCHEMBL16055166 0.81 ALDH1A1 (0.46) KDM4ELMNATACR2SSTR5ALDH1A1
SCHEMBL16055771 0.81 ALDH1A1 (0.56) KDM4ESSTR5ALDH1A1MAPTCRHBP
SCHEMBL16055312 0.81 TACR2 (0.54) KDM4ELMNATACR2HTR1AADRA1D
SCHEMBL16056330 0.80 MRGPRX4 (0.50) KDM4ELMNASSTR5KCNH2MRGPRX4
SCHEMBL16616064 0.80 ALDH1A1 (0.43) KDM4ESSTR5ALDH1A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772253-B2 Amide derivatives as somatostatin receptor 5 antagonists HOFFMAN-LA ROCHE INC. (US) 2010-08-10 US disclosed
EP-1893603-B1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
EP-1893603-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2008-03-05 EP disclosed
WO-2006128803-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 WO disclosed
US-20060276508-A1 Amide derivatives as somatostatin receptor 5 antagonists F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276508-A1 Amide derivatives as somatostatin receptor 5 antagonists SSTR5, SSTR3, SSTR1 KDM4E 3383/4885LMNA 3667/4885TACR2 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.